 |
|
A Comparison of Estrogen Replacement, Pravastatin, and Combined Treatment for the Management of Hypercholesterolemia in Postmenopausal Women
Michael H. Davidson, MD;
Lisa M. Testolin, RD, CNSD;
Kevin C. Maki, MS;
Serge von Duvillard, PhD;
Kathleen B. Drennan
Arch Intern Med. 1997;157(11):1186-1192.
Abstract
Objectives
To evaluate and compare the lipid-altering effects of conjugated estrogens and pravastatin, alone and in combination, in postmenopausal women with hypercholesterolemia.
Methods
This was a double-blind, randomized, placebo-controlled clinical trial with 4 parallel groups. Participants (N=76) were randomly assigned to receive conjugated estrogens, 0.625 mg/d; pravastatin sodium, 20 mg/d; conjugated estrogens plus pravastatin; or a placebo for 16 weeks.
Results
Primary end points were changes in serum lipid parameters. Among participants treated with conjugated estrogens, levels of non-high density lipoprotein cholesterol (non-HDL-C) (13.0%) and calculated low density lipoprotein cholesterol (LDL-C) (13.5%) decreased, while levels of HDL-C (22.5%) and triglycerides (4.2%) increased. Participants in the pravastatin group achieved reductions of 23.7% and 25.4% in non— HDL-C and calculated LDL-C levels, respectively. Levels of HDL-C increased slightly (3.7%) and triglycerides decreased by 12.1%. Among participants treated with a combination of conjugated estrogens plus pravastatin, the non—HDL-C (—25.2%) and calculated LDL-C (—28.7%) responses were similar to those of the pravastatin group, and the HDL-C response (21.2%) was similar to that observed in the conjugated estrogens group. Triglyceride levels remained similar to baseline ( —0.9%) in the combined treatment group.
Conclusions
Administration of conjugated estrogens resulted in potentially antiatherogenic changes in levels of non-HDL-C, HDL-C, and calculated LDL-C. The HDL-C response to combined treatment was similar to that observed in women taking conjugated estrogens alone, while the non-HDL-C and LDL-C responses to combined treatment were similar to those produced by pravastatin therapy alone. These findings support the position of the National Cholesterol Education Program that estrogen replacement, with a progestin where indicated, should be given consideration as a therapeutic option for the management of hypercholesterolemia in postmenopausal women.
Arch Intern Med. 1997;157:1186-1192
Author Affiliations
From the Chicago Center for Clinical Research, Chicago, Ill (Dr Davidson, Mss Testolin and Drennan, and Mr Maki), and the Department of Health, Physical Education, and Recreation, University of North Dakota, Grand Forks (Dr von Duvillard).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
New Markers for Cardiovascular Disease Risk in Women: Impact of Endogenous Estrogen Status and Exogenous Postmenopausal Hormone Therapy
Davison and Davis
J. Clin. Endocrinol. Metab. 2003;88:2470-2478.
ABSTRACT
| FULL TEXT
Statin Therapy, Cardiovascular Events, and Total Mortality in the Heart and Estrogen/Progestin Replacement Study (HERS)
Herrington et al.
Circulation 2002;105:2962-2967.
ABSTRACT
| FULL TEXT
Prevention and Treatment of Coronary Heart Disease: Who Benefits?
LaRosa
Circulation 2001;104:1688-1692.
ABSTRACT
| FULL TEXT
Cardiovascular Disease and Dyslipidemia in Women
Welty
Arch Intern Med 2001;161:514-522.
ABSTRACT
| FULL TEXT
The Role of Hormone Replacement Therapy in the Prevention of Postmenopausal Heart Disease
Mosca
Arch Intern Med 2000;160:2263-2272.
ABSTRACT
| FULL TEXT
Effects of simvastatin only or in combination with continuous combined hormone replacement therapy on serum lipid levels in hypercholesterolaemic post-menopausal women
Fak et al.
Eur Heart J 2000;21:190-197.
ABSTRACT
Alternatives to the Use of Estrogen in Postmenopausal Women
Pinkerton and Santen
Endocr Rev 1999;20:308-320.
ABSTRACT
| FULL TEXT
Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease
Herrington et al.
J Am Coll Cardiol 1999;33:2030-2037.
ABSTRACT
| FULL TEXT
Vascular Effects of Estrogen and Cholesterol-Lowering Therapies in Hypercholesterolemic Postmenopausal Women
Koh et al.
Circulation 1999;99:354-360.
ABSTRACT
| FULL TEXT
The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease
Sbarouni et al.
J Am Coll Cardiol 1998;32:1244-1250.
ABSTRACT
| FULL TEXT
THE BENEFIT OF ESTROGEN REPLACEMENT THERAPY IN HYPERCHOLESTEROLEMIA
JWatch General 1997;1997:2-2.
FULL TEXT
|
